Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isobutyl 6-formyl pterin (i6-FP) is a synthetic small molecule that acts as a potent antagonist of the Major Histocompatibility Complex-related protein 1 (MR1). MR1 is a non-polymorphic MHC class I-like molecule that presents microbial vitamin B metabolites to mucosal-associated invariant T (MAIT) cells. i6-FP is a derivative of 6-formylpterin (6-FP), a photodegradation product of folic acid. It binds to the antigen-binding cleft of MR1, stabilizing the molecule on the cell surface but failing to activate MAIT cells. By competitively inhibiting the binding of stimulatory microbial ligands, i6-FP suppresses MAIT cell activation and the subsequent production of pro-inflammatory cytokines such as IFN-gamma and TNF. Research indicates that i6-FP may have therapeutic potential in treating inflammatory conditions where MAIT cells play a pathogenic role, such as Ulcerative Colitis and Inflammatory Bowel Disease, without compromising intestinal barrier integrity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isobutyl 6-formyl pterin.